GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Carisma Therapeutics
The shares of Carisma, an oncology biotech company focused on cell therapy, reflect the potential of its scientific platform. The price trajectory is highly speculative and depends on the results of preclinical and early clinical trials.
Share prices of companies in the market segment - Pharma immune
Carisma Therapeutics is a biopharmaceutical company developing CAR-macrophage-based cell therapy that may be effective against solid tumors. We've categorized it under "Pharma: Immunology." The chart below shows how the market is valuing this innovative approach in immuno-oncology.
Broad Market Index - GURU.Markets
Carisma Therapeutics is an oncology company pioneering the development of CAR-macrophage-based cell therapy. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how investors are valuing this breakthrough technology.
Change in the price of a company, segment, and market as a whole per day
CARM - Daily change in the company's share price Carisma Therapeutics
For Carisma Therapeutics, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma immune
Carisma Therapeutics, Inc. is an oncology company. This chart illustrates the extreme volatility of the biotech sector. A comparison with CARM's performance, with its unique cell therapy platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Carisma Therapeutics is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex landscape of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Carisma Therapeutics
For Carisma Therapeutics, the year-to-date performance is a story of developing a new generation of cell therapy. Its 12-month market cap depends entirely on early clinical trial data for its platform, which uses macrophages to fight cancer. Success could be a breakthrough, offering a new way to attack solid tumors.
Annual dynamics of market capitalization of the market segment - Pharma immune
As an early-stage biotech company, Carisma is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cell therapy. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Carisma Therapeutics is a cutting-edge cell therapy company, and its stock is driven by lab news. Its year-over-year performance relative to the market isn't about economics, but rather about hope for a revolution in cancer treatment. Success in trials can boost the stock by hundreds of percent, demonstrating a complete disconnect from overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Carisma Therapeutics
Carisma Therapeutics is a pioneer in the development of CAR macrophage therapy. Being in the clinical stage, its monthly evaluation is entirely dependent on news. Trial results confirming the efficacy of its unique technology are the primary driver.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Carisma Therapeutics is a biotech company pioneering the development of CAR-based macrophage cell therapy. This is a novel approach in immuno-oncology that may be effective against solid tumors. The graph below illustrates the dynamics of the biotech sector, where the search for new types of cell therapy is the holy grail.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Carisma Therapeutics is a biotech company developing innovative cell therapies for cancer treatment. Its stock is a classic venture capital story, where everything hinges on the success of clinical trials. Its performance is completely disconnected from the broader market and is determined by scientific breakthroughs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Carisma Therapeutics
Carisma Therapeutics is a pioneer in developing CAR-macrophage therapy for cancer treatment. As an early-stage biotech, its weekly stock price performance is entirely dependent on scientific data and progress in clinical trials.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Carisma Therapeutics develops innovative cell therapy. This chart allows us to separate the stock's reaction to the company's unique scientific data from the overall sentiment in the immunopharmaceutical sector. Is the weekly price movement specific to Carisma or is it an industry trend?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Carisma Therapeutics is an oncology biotech company. Its success depends on scientific breakthroughs. The chart clearly shows how often the company's shares move against the broader market in response to research data releases. How immune is it to overall market volatility?
Market capitalization of the company, segment and market as a whole
CARM - Market capitalization of the company Carisma Therapeutics
The Carisma Therapeutics chart shows a bet on a new generation of cell therapy. This biotech's market cap reflects investors' faith in its CAR macrophage technology for cancer treatment. This is a highly volatile scientific hope curve, typical for clinical-stage companies.
CARM - Share of the company's market capitalization Carisma Therapeutics within the market segment - Pharma immune
Carisma Therapeutics is a pioneer in the development of CAR-macrophage-based cell therapy, a novel approach to cancer treatment. In the immune pharmaceutical segment, its market capitalization reflects the revolutionary potential of its platform. The company's size reflects a bet that its technology will prove effective where other cell therapies (such as CAR-T) have failed.
Market capitalization of the market segment - Pharma immune
Carisma Therapeutics is a pioneer in macrophage-based cell therapy. How big is this arena? The chart below shows the pulse of the immunopharmaceutical sector. Its high volatility reflects both the enormous hopes for the next generation of "living drugs" and the high risks associated with their development.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Carisma Therapeutics chart shows how the market values a cutting-edge cell therapy technology. The valuation of the company, which is developing a cancer treatment based on genetically modified macrophages, is a venture bet on a completely new approach. This chart is full of scientific risk and enormous potential.
Book value capitalization of the company, segment and market as a whole
CARM - Book value capitalization of the company Carisma Therapeutics
For Carisma Therapeutics, a pioneer in macrophage-based cell therapy, book value is its physical foundation: laboratories, manufacturing contracts, and significant financial reserves for clinical trials. The chart below shows how the company built this physical foundation.
CARM - Share of the company's book capitalization Carisma Therapeutics within the market segment - Pharma immune
Carisma Therapeutics is a pioneer in cell therapy. Its core assets are its cutting-edge laboratories and manufacturing facilities for creating its unique CAR macrophages. These facilities are the physical launchpad for a new era in cancer treatment. The chart shows the company's control over this unique biotech infrastructure.
Market segment balance sheet capitalization - Pharma immune
Carisma Therapeutics is a cell therapy company. Pharmaceuticals, as the chart shows, are capital-intensive. Carisma is a prime example. Its business requires the construction of its own highly complex and expensive laboratories and factories to produce cell therapy products.
Book value of all companies included in the broad market index - GURU.Markets
Carisma's assets are not drugs, but cutting-edge laboratories and a pilot plant for developing innovative cell therapy based on genetically engineered macrophages for cancer treatment. The book value reflects the material resources for this complex scientific research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Carisma Therapeutics
Carisma Therapeutics is a pioneer in the development of macrophage-based cell therapy (CAR-M). Its market capitalization is a pure bet on this new and unproven technology. The chart shows how investors view its potential for treating solid tumors, where other cell therapies have not yet been very successful.
Market to book capitalization ratio in a market segment - Pharma immune
Carisma Therapeutics is a pioneer in the development of CAR macrophages, a new approach to cancer cell therapy. The company's valuation represents a promise of a revolution in oncology. The chart shows that its market capitalization is a bet on the success of this cutting-edge scientific platform.
Market to book capitalization ratio for the market as a whole
Carisma Therapeutics is a biotech company focused on cell therapy. Its valuation is based almost entirely on investor expectations regarding the success of its scientific platform. This chart illustrates the wide gap between market value and book value, typical for early-stage companies.
Debts of the company, segment and market as a whole
CARM - Company debts Carisma Therapeutics
Carisma Therapeutics is a biotech company developing innovative cell therapy based on CAR macrophages. This is a cutting-edge scientific field that requires significant investment in research and clinical trials. This chart shows how the company is raising significant funds to finance its unique and very expensive scientific platform.
Market segment debts - Pharma immune
Carisma Therapeutics is a clinical-stage biotech company pioneering the development of CAR-macrophage therapy. This innovative technology requires significant investment in R&D. This chart shows its financial position, which is entirely dependent on its ability to raise capital to fund its cutting-edge research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Carisma Therapeutics
Carisma Therapeutics is a biotech company developing cell therapies for cancer. This chart shows its financial structure. As with most companies in clinical development, debt is a huge risk. All resources should be directed toward research, not interest payments, so equity financing is essential.
Market segment debt to market segment book capitalization - Pharma immune
Carisma Therapeutics is a pioneer in developing CAR-based macrophage cell therapy, a new approach to fighting cancer. This is a cutting-edge, but highly risky, field. The chart shows the overall debt burden in the biotech sector, highlighting the enormous financial resources the company requires to advance its innovative technology.
Debt to book value of all companies in the market
Carisma Therapeutics is a biotech company working at the forefront of cancer cell therapy. This is fundamental science, requiring massive investment for years to come. This chart clearly shows that for such pioneering companies, debt financing is not an option, and their future depends solely on investors' faith in their scientific approach.
P/E of the company, segment and market as a whole
P/E - Carisma Therapeutics
For Carisma Therapeutics, a company developing cell therapy, the P/E ratio is not a useful metric. The company has no profit, and its valuation on this chart is arbitrary. The real value comes from investors' faith in its unique scientific platform and the potential for future cancer treatments.
P/E of the market segment - Pharma immune
Carisma Therapeutics is a pioneering biopharmaceutical company developing cell therapies based on engineered macrophages for the treatment of cancer. This chart shows the average valuation for the sector, helping to understand how the market views this innovative and complex approach to immuno-oncology.
P/E of the market as a whole
Carisma Therapeutics is a biotech company developing innovative macrophage-based cell therapy for cancer treatment. Its valuation is a pure bet on the success of this unique technology. It is unrelated to the general economic cycles illustrated by this chart. Its fate is decided in clinics and by regulators.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Carisma Therapeutics
Carisma Therapeutics is a biotech company pioneering the development of CAR-macrophage-based cell therapy for the treatment of solid tumors. This chart reflects investor expectations for this innovative technology. The valuation is based on the long-term potential to offer a new approach to cancer treatment where CAR-T therapy is less effective.
%20P%2FE%20Carisma%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Carisma-Therapeutics&v=1772513909239 "Chart of the company's future (projected) P/E Carisma Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Carisma Therapeutics is a biopharmaceutical company developing CAR-macrophage-based cell therapy for cancer treatment. Its valuation relative to other cell therapy companies reflects investors' opinions of its innovative approach, betting that its technology will prove effective where other approaches have failed.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513909260 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Carisma Therapeutics is a pioneer in the development of CAR macrophages, a new approach to cell therapy for cancer treatment. This is a high-risk, cutting-edge field. This chart illustrates investors' overall risk appetite. For companies with breakthrough but unproven technologies, a positive market environment makes it easier to attract significant capital for research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513909310 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Carisma Therapeutics
Carisma Therapeutics is a biotech company pioneering the development of CAR macrophages, a novel approach to cancer cell therapy. The financial performance shown here reflects the company's massive investment in this cutting-edge science. The company's future depends on the success of its unique platform in clinical trials.
Profit of companies in the market segment - Pharma immune
Carisma Therapeutics is a pioneer in developing CAR-macrophage-based cell therapy for cancer treatment. This chart reflects the financial health of the immune therapy sector. It shows whether this cutting-edge field of oncology is financially viable or whether it remains an area of expensive, high-risk research.
Overall market profit
Carisma Therapeutics is developing innovative CAR-macrophage-based cell therapy for cancer treatment. This is cutting-edge research. The company's value is entirely dependent on clinical trial success. Macroeconomic cycles, as seen in this chart, are secondary to scientific breakthroughs for Carisma Therapeutics.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Carisma Therapeutics
Carisma Therapeutics is a biotech company developing innovative macrophage-based cell therapy for cancer. Its future revenue forecast is a long-term bet on the success of this new technology. This chart reflects analysts' confidence in the company's scientific platform and its potential to create a breakthrough in immuno-oncology.
%20profit%20of%20the%20company%20Carisma%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Carisma-Therapeutics&v=1772513909401 "Graph of future (projected) profit of the company Carisma Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Carisma Therapeutics is a pioneer in the development of CAR macrophages, a new approach to cellular cancer immunotherapy. Unlike CAR-T, this technology may be effective against solid tumors. This graph shows the outlook for immunopharmaceuticals, illustrating the hopes for scientific breakthroughs that could open new horizons in treating the most complex forms of cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513909406 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
For Carisma Therapeutics, which operates in the cutting-edge field of immunotherapy, this schedule is important for the investment climate. Expectations of economic growth are increasing investor appetite for risky but potentially breakthrough biotechnologies. During downturns, raising funding for early-stage R&D becomes more difficult.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513909470 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Carisma Therapeutics
Carisma Therapeutics is developing innovative cell therapy for cancer treatment. This figure, without revenue, is a pure measure of expectations. Investors evaluate solely scientific potential and potential future commercial success.
P/S market segment - Pharma immune
Carisma Therapeutics is a biopharmaceutical company developing innovative CAR-macrophage-based cell therapy for the treatment of cancer. This chart shows the average valuation in the immunopharmaceutical sector. It reflects investor confidence in this new approach to treating solid tumors and the potential of Carisma's platform.
P/S of the market as a whole
Carisma Therapeutics Inc. is a biotech company developing innovative CAR-macrophage-based cell therapy for the treatment of solid tumors. The company's valuation is based on the potential of this new technology. This chart shows the premium investors are paying for breakthrough approaches in oncology compared to average revenue estimates.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Carisma Therapeutics
Carisma Therapeutics is a pioneer in the development of CAR macrophages, a new approach to cancer cell therapy. The company's valuation is based on the future potential of this innovative technology. The chart shows how much investors believe this unique treatment will be effective and generate billions in revenue.
%20P%2FS%20Carisma%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Carisma-Therapeutics&v=1772513909546 "The graph of the company's future (projected) P/S Carisma Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Carisma Therapeutics is a biotech company pioneering the development of CAR-macrophage-based cell therapy. This novel approach to cancer immunotherapy may be effective against solid tumors. This chart shows how investors view the potential of this innovative and risky technology compared to other companies in the sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513909593 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
This indicator reflects the market's faith in cell therapy. For Carisma Therapeutics, a company developing CAR-macrophage-based therapy, it reflects appetite for breakthrough technologies. Market optimism is essential for funding a new approach in immuno-oncology that could be effective against solid tumors.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513909654 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Carisma Therapeutics
Carisma Therapeutics is a biopharmaceutical company pioneering the development of CAR macrophages, a novel approach to cellular cancer immunotherapy. This chart represents revenue from collaborations with major pharmaceutical companies. In the future, it will show revenue from sales of this innovative therapy, aimed at treating solid tumors.
Sales of companies in the market segment - Pharma immune
Carisma Therapeutics is a biotech company pioneering the development of CAR-macrophage-based cell therapy for cancer treatment. This chart illustrates the growth of the immunopharmacology market. Carisma's approach represents a new direction in cell therapy that could be effective against solid tumors, addressing one of the main challenges in oncology.
Overall market sales
Carisma Therapeutics is a biotechnology company developing cell therapies for cancer treatment. Its development depends on the success of clinical trials and investment. The overall economic environment, shown in this chart, influences the availability of venture capital for funding advanced and capital-intensive medical technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Carisma Therapeutics
Carisma Therapeutics is a pioneer in developing a new class of cancer cell therapy based on CAR macrophages, an alternative to the more common CAR-T cells. The company's future depends on the success of its early clinical trials. This graph reflects analysts' confidence in the scientific potential of this innovative immunotherapy platform.
%20sales%20of%20the%20company%20Carisma%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Carisma-Therapeutics&v=1772513909755 "Schedule of future (projected) sales of the company Carisma Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Carisma Therapeutics is a biotech company developing CAR-macrophage-based cell therapy for cancer treatment. This chart shows expectations for the immune pharmaceutical sector. It illustrates the strong interest in new approaches to cell therapy, where Carisma is developing its unique platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513909772 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Carisma Therapeutics is a biopharmaceutical company pioneering the development of CAR-macrophage-based cell therapy for the treatment of cancer. Its future depends on the success of clinical trials. The overall economic situation, reflected in this chart, influences the amount of venture capital funding available for advanced biotech platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513909834 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Carisma Therapeutics
Carisma Therapeutics is developing innovative macrophage-based cell therapy for cancer treatment. This chart shows the financial picture at the advanced research stage. Negative values represent investments in a unique scientific platform that, if successful, could open up a completely new approach in immuno-oncology.
Market segment marginality - Pharma immune
Carisma Therapeutics is a biotech company developing innovative cell therapies for cancer treatment. For a research-stage company, this chart is an important benchmark. It shows the average profitability achieved in its sector, illustrating the financial potential Carisma aspires to achieve if commercially successful.
Market marginality as a whole
Carisma Therapeutics is a biopharmaceutical company developing innovative cell therapy based on CAR macrophages. This overall market profitability chart is irrelevant to the company. Its potential lies in creating a breakthrough technology for cancer treatment. Success will be determined by clinical results and science, not the stock market.
Employees in the company, segment and market as a whole
Number of employees in the company Carisma Therapeutics
Carisma Therapeutics is a pioneer in the development of CAR-macrophage-based immunotherapy, a novel approach to cancer treatment. This chart shows the team of scientists and clinicians advancing this cutting-edge technology. Their number reflects their focus on research and development in one of the hottest areas of biotech.
Share of the company's employees Carisma Therapeutics within the market segment - Pharma immune
Carisma Therapeutics is a pioneer in the development of CAR macrophages, a new approach to cancer cell therapy. This chart shows the percentage of leading immunologist and cell engineering specialists the company attracts in this cutting-edge field. It reflects its concentration of unique scientific talent to create next-generation therapies.
Number of employees in the market segment - Pharma immune
Carisma Therapeutics is a pioneer in the development of macrophage-based cell therapy (CAR-M), a new approach to fighting cancer. This graph illustrates how new ideas are constantly emerging at the forefront of immuno-oncology, requiring top scientists to bring them to fruition and laying the foundation for the medicine of the future.
Number of employees in the market as a whole
Carisma Therapeutics is a cutting-edge biotherapeutics company whose work requires elite scientific talent. This chart shows the overall workforce, but its innovative potential is determined by these companies. Carisma is contributing to the formation of a highly skilled talent pool, which is key to future economic growth.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Carisma Therapeutics (CARM)
Carisma Therapeutics is a biotech company developing cell therapy (CAR macrophages). This chart is a classic example of intellectual capital valuation. The company's value is based solely on the potential of its unique scientific platform. The chart shows how highly the market values these future breakthrough drugs per scientist.
%20of%20the%20company%20Carisma%20Therapeutics%20(CARM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Carisma-Therapeutics-CARM&v=1772513910189 "Chart of market capitalization per employee (in thousands of dollars) of the company Carisma Therapeutics (CARM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Carisma Therapeutics develops cutting-edge cell therapy for cancer. The company's value is based almost entirely on its research potential. This chart shows how highly the market values the intellectual contribution of each scientist on the team. This is a bet by investors that their approach will prove to be a breakthrough in oncology.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513910195 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Carisma Therapeutics is a biopharmaceutical company developing immunotherapy based on CAR macrophages. This chart reflects the market value of a single employee, highlighting the enormous value of cutting-edge scientific platforms.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513910219 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Carisma Therapeutics (CARM)
Carisma Therapeutics is a clinical-stage biotech company developing cell therapies. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company invests in each scientist to conduct R&D in the cutting-edge field of immuno-oncology.
%20Chart%20Carisma%20Therapeutics%20(CARM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Carisma-Therapeutics-CARM&v=1772513910258 "Company Profit Per Employee (in thousands of dollars) Chart Carisma Therapeutics (CARM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Carisma Therapeutics is a biotech company developing CAR-macrophage-based cell therapy for cancer treatment. Its value lies in its unique scientific platform and team of researchers. This graph for such development-stage companies often shows negative profits, reflecting significant investments in R&D in anticipation of a future commercial breakthrough.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513910293 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Carisma Therapeutics (CARM) is a clinical-stage biotech company developing a cell therapy (CAR-Macrophage) for the treatment of solid tumors (cancer). It's an R&D company. This chart shows the average profitability per employee across the market. For CARM (which is not yet profitable), this is a benchmark: in biotech, a small team of scientists can create a product that will significantly exceed this average in the future.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513910323 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Carisma Therapeutics (CARM)
Carisma Therapeutics is a biotech company developing cell therapies for cancer. For a company at the forefront of science, this chart is a reflection of the future. Current lows could give way to sharp growth if its innovative platform is successful and its products reach the market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Carisma-Therapeutics-CARM&v=1772513910331 "Sales chart per company employee Carisma Therapeutics (CARM)")
Sales per employee in the market segment - Pharma immune
Carisma Therapeutics is a biotech company developing CAR-macrophage-based therapies (a novel approach in immuno-oncology). The company is in the R&D stage. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of Carisma's scientific team.
Sales per employee for the market as a whole
Carisma Therapeutics is a clinical-stage biotech company developing innovative cell therapy (CAR macrophages) for the treatment of cancer. The company has no commercial revenue, which is irrelevant. Its value lies in the potential of its R&D team to create a new class of drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Carisma Therapeutics (CARM)
Carisma Therapeutics is a biotech company working at the cutting edge of science. They are developing CAR-M (carbohydrate-modified macrophage) therapy for cancer treatment. This is an extremely complex and unproven technology. This graph shows the odds that this scientific hypothesis will be proven wrong and the company will fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Carisma-Therapeutics-CARM&v=1772513910413 "Short Shares Chart for the Company Carisma Therapeutics (CARM)")
Shares shorted by market segment - Pharma immune
Carisma Therapeutics is a biotech company developing CAR-macrophage (immune cell)-based cell therapy for the treatment of solid tumors. This chart reflects the total short position in the immuno-oncology sector. High values indicate general investor skepticism about the success of cell therapy in treating solid tumors, where breakthroughs have been few.
Shares shorted by the overall market
Carisma Therapeutics is a biotech developing CAR-M (macrophage) therapy. This is a complex R&D area. This chart illustrates the overall market pessimism. When investors are fearful, they are reluctant to fund "scientific experiments." They see the R&D costs and sell the stock, fearing the technology won't work.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Carisma Therapeutics (CARM)
This chart shows the faith in Carisma's CAR-T therapy. The company is a pioneer in the use of CAR macrophages (a new type of cell) to treat cancer. "Overbought" (above 70) is indicated by positive preclinical data or a partnership with Big Pharma. This is a very early and risky technology, and any clinical failures lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Carisma-Therapeutics-CARM&v=1772513910498 "RSI 14 indicator chart for the company's stock Carisma Therapeutics (CARM)")
RSI 14 Market Segment - Pharma immune
Carisma (CARM) is "CAR-T" 2.0 (Macrophages). They "engineer" *macrophages* (another type of immune cell)—creating a "universal" cure for *solid* tumors. The "Pharma-immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It helps us understand: is CARM's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Carisma Therapeutics (CARM) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CARM (Carisma Therapeutics)
Carisma Therapeutics is a biotech company developing cellular therapy (CAR-Macrophage), a novel approach that uses macrophages to fight cancer. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of this innovative R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CARM-Carisma-Therapeutics&v=1772513910731 "A chart showing analyst consensus forecasts for the expected stock price. CARM (Carisma Therapeutics)")
The difference between the consensus estimate and the actual stock price CARM (Carisma Therapeutics)
Carisma is a biotech pioneer developing macrophage-based (CAR-M) cell therapy for the treatment of solid tumors. This is a unique approach in immuno-oncology. This chart measures the gap between the current price and the consensus target price. It demonstrates the enormous, yet risky, potential analysts see in this research.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CARM-Carisma-Therapeutics&v=1772513910766 "A chart showing the difference between the consensus forecast and the actual stock price. CARM (Carisma Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Carisma is a biotech pioneer developing cell therapy based on "CAR macrophages" (instead of T cells) to attack cancer. This R&D is at the cutting edge of science. This chart shows the overall expectations of analysts across the immunopharmacology sector. It reveals whether experts believe in new cell therapy platforms.
Analysts' consensus forecast for the overall market share price
Carisma Therapeutics is a biotech company developing cell therapy (CAR-macrophages) for the treatment of cancer. This is a high-risk sector, where success depends on the results of clinical trials. This chart reflects the overall risk appetite in the market. For Carisma, which has yet to generate revenue, the overall analyst optimism (the rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Carisma Therapeutics
Carisma is an R&D pioneer working on macrophages. Instead of using T cells (CAR-T), they program macrophages (another type of immune cell) to attack solid tumors. This is a bet on the next generation of cell therapy. This graph is a clear indicator of faith in their R&D, reflecting their (very risky) progress in clinical trials.
AKIMA Market Segment Index - Pharma immune
Carisma Therapeutics (CARM) is a pioneer in cell therapy. They are developing CAR macrophages—massive immune system predators designed to penetrate and destroy solid tumors. The chart shows the segment's average index, helping investors assess how this cutting-edge but risky technology stacks up against the market average.
The AKIM Index for the overall market
Carisma Therapeutics is a pioneer in macrophage-mediated cell therapy (CAR-M) for the treatment of solid tumors. This market average chart is an indicator of risk appetite. It illustrates the macro backdrop critical to funding this unique immuno-oncology platform.
